Monday, July 24, 2017

biOasis Appoints Catherine London, Executive Vice President, Head of Corporate Communications and Investor Relations

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) welcomes Catherine London as executive vice president, head of corporate communications and investor relations, effective immediately. London will report...

biOasis CEO Purchases Shares

On the back of his recent CEO update to shareholders, in which he expressed great enthusiasm for the Transcend Platform and the opportunity in...

biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders

Tailwinds' Take: this long awaited update from the new CEO shows that he's a thoughtful, reasoned leader who understands the technology and its place...

biOasis to present at Global Chinese Financial Forum

Tailwinds' Take: Per Mark Day, "(the Forum) is my first opportunity to publicly express my excitement about biOasis and to discuss our strategies for the Transcend Platform going...

biOasis to Present at the 16th International Postgraduate Course on Lysosomal Storage Disorders

Tailwinds' Take: Lysosomal Storage Disorders is an area in which Transcend should be highly effective. Dr. Scarpa is also presenting at this course, after...

biOasis Appoints Mark Day, Ph.D., as Chief Executive Officer and Director

Tailwinds' Take: Dr. Day is a well respected thought leader and proven business development executive. The combination of his talents with the pipeline of...

biOasis Closes Upsized Private Placement

Last night, biOasis Technologies announced that they have closed their non-brokered placement. The Company  issued 5,797,795 units (each a "Unit") at a price of CDN$0.70 per...

biOasis Announces Oversubscription of Financing

Tailwinds' Take: This is THE catalyst we have been expecting from biOasis. While it took a long time to get this deal done, I...

biOasis Arranges $3.15-Million Private Placement

Tailwinds' Take: This is the catalyst for which the market has been waiting. With this funding, they will garner "in human" results from a Phase...

biOasis: The Storm Before The Calm?

Shares in biOasis have been under pressure for a while, the stock having drifted down from last year’s high of $2.05 to where it’s...

Prolonging Life…biOasis Platform Represents Hope for CNS Diseases

Thursday, I went to a funeral Mass of one of our neighbors.  She had always been in good shape, never overweight, instead on the...

Understanding the biOasis Drug Delivery Platform

True Story: I fell in love with biOasis at a speed dating event. It was, of course, speed dating for investors. Fifteen minutes with a...

biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured...

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address